Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Merck
Mallinckrodt
Moodys
Express Scripts

Last Updated: January 27, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Dovitinib


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Dovitinib?

Dovitinib is an investigational drug.

There have been 51 clinical trials for Dovitinib. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2011.

The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and M.D. Anderson Cancer Center.

Recent Clinical Trials for Dovitinib
TitleSponsorPhase
Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic CarcinomaSeoul National University HospitalPhase 2
Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoPhase 2
Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic CancerNational Cancer Institute (NCI)Phase 1

See all Dovitinib clinical trials

Clinical Trial Summary for Dovitinib

Top disease conditions for Dovitinib
Top clinical trial sponsors for Dovitinib

See all Dovitinib clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Merck
Mallinckrodt
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.